C4 Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| C4 Therapeutics, Inc. | ||
| Date: February 26, 2026 | By: | /s/ Andrew J. Hirsch |
|---|---|---|
| Andrew J. Hirsch | ||
| President and Chief Executive Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Andrew J. Hirsch | President, Chief Executive Officer, and Director | February 26, 2026 |
| Andrew J. Hirsch | (Principal Executive Officer) | |
| /s/ Kendra R. Adams | Chief Financial Officer and Treasurer | February 26, 2026 |
| Kendra R. Adams | (Principal Financial Officer) | |
| /s/ Mark Mossler | Chief Accounting Officer | February 26, 2026 |
| Mark Mossler | (Principal Accounting Officer) | |
| /s/ Ronald Cooper | Chairman and Director | February 26, 2026 |
| Ronald Cooper | ||
| /s/ Kenneth C. Anderson, M.D. | Director | February 26, 2026 |
| Kenneth C. Anderson, M.D. | ||
| /s/ Laura Bessen, M.D. | Director | February 26, 2026 |
| Laura Bessen, M.D. | ||
| /s/ Stephen Fawell, Ph.D. | Director | February 26, 2026 |
| Stephen Fawell, Ph.D. | ||
| /s/ Donna Grogan, M.D. | Director | February 26, 2026 |
| Donna Grogan, M.D. | ||
| /s/ Utpal Koppikar | Director | February 26, 2026 |
| Utpal Koppikar | ||
| /s/ Stephen L. Hoerter | Director | February 26, 2026 |
| Stephen L. Hoerter | ||
| /s/ Owen Hughes | Director | February 26, 2026 |
| Owen Hughes | ||
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Report of Independent Registered Public Accounting Firm | F-2 |
|---|---|
| Consolidated Balance Sheets | F-4 |
| Consolidated Statements of Operations and Comprehensive Loss | F-5 |
| Consolidated Statements of Stockholders’ Equity | F-6 |
| Consolidated Statements of Cash Flows | F-7 |
| Notes to Consolidated Financial Statements | F-8 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.